Ajinomoto Co., Ltd.

Ea Pharma Co., Ltd.

Tadakiyo Nakagawa

Tamotsu Suzuki

Munetaka Tokumasu

Tatsuhiro Yamada

Kazuyuki Sagi

Takashi Kayahara

Tatsuya Okuzumi

Yoichiro Shima

Shunji Takehana

Yasuhiro Tanaka

Masahiro Murata

Kaoru Yoshida

Kayo Matsumoto

Koji Ohsumi

Shinichi Fujita

Masataka Shoji

Taisuke Ichimaru

Takahiro Koshiba

Yumiko Fukuda

Youji Yamada

Yoriko Yamamoto

Akira Nakayama

Manabu Suzuki

Toshihiko Yoshimura

Masayuki Sugiki

Noriyasu Kataoka

Mitsuo Takahashi

Akira Takahara

Masaru Takayanagi

Koichi Fujita

Itsuya Tanabe

Misato Noguchi

Kohichi Fujita

Shunsuke Kageyama

Yuka Ikenoue

Ayatoshi Andou

Hajime Ito

Kenji Shinkai

Kazuyuki Ubukata

Kaoru Takenaka

Masanao Yoshida

Tomoyuki Tagami

Hideki Matsumoto

Shingo Makino

Akira Chiba

Tetsuo Yano

Sen Takeshita

Kuniya Sakurai

Kaori Kobayashi

Tomomi Yoshida

Ariko Kodaira

Yuki Kajigaya

Yoshitomo Chujo

Shunsuke Fukuda

Hiroki Inoue

Kazumi Tashiro

Yoshitomo Chujoh

Syunsuke Fukuda

Masahiro Yamanashi

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Heteroarylcarboxylic acid ester derivative

Provided is a compound represented by the following general formula (I), or a pharmaceutically acceptable salt thereof. This novel compound has a glycogen-synthase activation ability, but activates a receptor PPAR to a low degree and is highly safe.  In the formula, Ar is an aromatic carbocyclic ring or a heterocyclic ring; and Aris represented by any one of the following rings and the like. 

Pharmaceutical composition for treating diabetes

Compounds represented by the following formula (I); wherein each symbol is as defined in the specification,are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Specific phenylalanine derivatives and analogues thereof have an antagonistic activity to &#x3b1;4 integrin. They are used as therapeutic agents for various diseases concerning &#x3b1;4 integrin.

Phenylalanine derivatives

Amide derivatives represented by the formula (I): wherein:

Amide derivative

A pharmaceutical composition containing a heterocyclic compound of the formula (I) wherein each symbol is as defined in the specification, an isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient has a superior TNF-&#x3b1; production suppressing action. Accordingly, it is useful for the prophylaxis or treatment of various diseases caused by abnormal production of TNF-&#x3b1;.

Heterocyclic compounds

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

Ether derivative

Benzamidine derivatives of the following formulae or analogs thereof, i.e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants 

Benzamidine derivatives

The inventive subject matter relates to compounds, pharmaceutical compositions, and kits containing a heterocyclic compound represented by the formula (I) wherein R is an alkyl group optionally having substituent(s) etc., X is an amino group optionally having substituent(s), Yand Yare nitrogen atoms etc., an isomer or solvate thereof or a pharmaceutically acceptable salt thereof as an active ingredient.

Aminoisoquinoline derivatives of the following formulae or analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an excellent effect of inhibiting activated blood-coagulation factor X, and they are useful as anticoagulants or agents for preventing or treating thrombi or emboli.

Aminoisoquinoline derivatives

The present invention provides benzodiazepine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof. The compounds of the present invention have an excellent effect of inhibiting activated blood-coagulation factor X. These compounds are usable as agents for treating various diseases concerned with the activated blood-coagulation factor X.

Benzodiazepine derivatives

Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

Benzamidine derivative

Growing community of inventors

Kawasaki, Japan

Tadakiyo Nakagawa